© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
June 16th 2021, 9:00pm
The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.
June 10th 2021, 1:00pm
Treatment with this combination was associated with encouraging clinical responses in this patient population.
June 8th 2021, 4:00pm
Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.
June 7th 2021, 9:00pm
Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
April 28th 2021, 12:30pm
Don’t let your disease define you
April 23rd 2021, 9:00pm
Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.
April 22nd 2021, 9:00pm
Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.
April 16th 2021, 12:00pm
Navigating life with blood cancer
March 17th 2021, 12:00pm
March 3rd 2021, 7:00pm
Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.
Adding Darzalex to Standard of Care May Improve Survival in Newly Diagnosed Multiple Myeloma
A ‘Turning Point’ for Metastatic NSCLC Treatment
My Daughter, the Learning Opportunity
Expert Breaks Down Misconceptions About COVID-19 Vaccine